samedan logo
 
 
 
spacer
home > pmps > summer 2015 > welcome to the parenterals universe
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Welcome to the Parenterals Universe

Ever since the Big Bang a mere 13 billion years ago, the universe has been expanding – time, space, matter and energy shifting and evolving in infinite complexity. It may be much more of a known quantity, but our own professional universe – pre-filled and injection technology – has also seen some major advancements and changes, albeit on a slightly smaller scale.

This supplement, produced by our media partner PMPS to coincide with PDA Europe’s The Universe of Pre-filled Syringes and Injection Devices conference on 3-4 November, offers expert insight into some of the main trends and concerns in the parenterals galaxy.

It also previews the big event itself, which is a must-attend for many PMPS readers. Taking place at the Austria Center in Vienna, speakers will discuss and explore an extensive range of topics around the science, technology and manufacture of injectables.

As Conference Chair, and a member of the Scientific Program Planning Committee behind the scenes, I’m anticipating a vibrant and successful event, full of debate and discovery.

During my 20 plus years in the pharmaceutical industry, I’ve witnessed the considerable progress that has been made – particularly in my specialist areas of aseptic processing and lyophilisation in devices – and this year’s event will bring us right up to date, with the latest in the areas of components, formulation, marketing and regulation.

Keynote presentations will include Pfizer’s Daniele Russo on addressing unmet product and technology needs in developing countries, and Paul Jansen from Sanofi on change management. There will also be various parallel tracks for the delegates – drawn from the science, regulatory and industry spectrum – to choose from, including next-generation systems, fill-finish, labelling, quality metrics and human factors. And around the conference, a wider programme of workshops, training courses and networking events will be available to take advantage of.

PDA Europe was established in 2006 as a subsidiary of the Parenteral Drug Association in the US. With 10,000 members worldwide, the non-profit organisation is committed to developing scientifically sound, practical technical information and resources for the pharma community. PDA’s tagline is ‘Connecting People, Science and Regulation’ – and this November’s event is a sure sign that it’s keeping that promise.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement